Medicalook
Medicalook

Almotriptan

http://www.medicalook.com
Almotriptan

Almotriptan review





Almotriptan, also known by the trade names of Axert and Almogran, belongs to a class of drugs called 5-HT1 agonists. It is a drug that eases the pain connected with migraine by narrowing the swelling blood vessels around the brain. This medicine is mostly available in tablet form and contains a water-soluble white to slightly yellow powder.

This prescription drug is mainly used by patients to manage migraines, although it can be also used to treat hepatitis and renal impairment as well. An Axert- or Almogran-brand product usually has 6.25 to 12.5 milligrams worth of almotriptan in each tablet.

Controlled clinical tests prove that single doses of 6.25 milligrams and 12.5 milligrams of almotriptan tablets were very successful in acute migraine therapy for adults, with the heavier 12.5 milligram dose being the more effective of the two dosages. Take note that individual response to the drug is on a case-to-case basis, so dosage must depend on the patient himself. Consult your doctor or pharmacist in order to get a proper almotriptan prescription.

In any case, the maximum daily dose of almotriptan for hepatitis treatment shouldn't go beyond 12.5 milligrams over a twenty-four hour period, while a dose of 6.25 milligrams should be utilized for the initial dose. Equally, the maximum daily dose for patients with severe renal impairment should also not exceed 12.5 milligrams per day and the starting dose of 6.25 milligrams should also be used.

The most typical side effects during almotriptan treatment are dry mouth, paresthesia, headache, somnolence, and nausea. Long-term, open-label research for patients who were allowed to treat multiple attacks for up to one year have revealed that 5% of the patients (or 63 of 1,347 patients) withdrew from continued therapy because of the harshness of the side effects.

Life-threatening cardiac events like coronary artery vasospasm and myocardial infarction have happened in patients undergoing almotriptan therapy even though they are exceedingly rare and most have been found in patients with risk factors prognostic of CAD (coronary artery disease). Other side effects reported in relation with drugs of this class include ventricular fibrillation, ventricular tachycardia, myocardial infarction, transient myocardial ischemia, and coronary artery vasospasm.

Severe disturbances in cardiac rhythm and even death have occurred within a few hours following the administration of this drug and other 5-HT1 agonists. Of course, the incidence of this particular side effect is very rare, especially when you consider the large number of patients using 5-HT1 agonists that have not suffered from these consequences. If you have a history of uncontrolled high blood pressure, cardiovascular ischemia, stroke, or heart attack, notify your doctor immediately.

Moreover, certain drugs taken along with almotriptan can result in potentially fatal drug interactions. As such, you should not take MAO inhibitors like tranylcypromine, selegiline, procarbazine, phehelzine, linezolid, and furazolidone for at least two weeks before or after taking this medication. You should also not take any other triptan-type migraine medications like sumatriptan and zolmitriptan or ergot-type drugs like methysergide, ergotamine, and dihydroergotamine within 24-hours of taking this drug.

It is currently unknown whether or not almotriptan can pass into human milk, so a nursing mother should avoid breastfeeding her child altogether while taking this medication. She should also consult her doctor for more information. Moreover, the effectiveness and safety of almotriptan in children have not been established as well, so this drug is not advised for patients below eighteen years of age.

Caution should be exercised by elderly patients taking this drug; a lowered dose may be prescribed to them depending on their body's current cardiac, renal, and hepatic function. As always, doctor consultation is important.

Almotriptan has the following structural formula:

Chemical structure of almotriptan


• Molecular formula of almotriptan is C17H25N3O2S
• Chemical IUPAC Name is N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine
• Molecular weight is 335.465 g/mol
Almotriptan available : 6,25mg tablets and 12,5mg tablets

Brand name(s): Axert, Eletriptan

  Your Almotriptan review